Avian Influenza Clinical Trial
Official title:
A Phase II Study in Healthy Adults 18-64 Years Old to Assess the Safety, Reactogenicity and Immunogenicity of a Seqirus A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without MF59(R) Adjuvant
This is a randomized, double-blinded, Phase II study in healthy males and non-pregnant females, 18-64 years of age. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of a pre-pandemic 2017 monovalent inactivated influenza A/H7N9 virus vaccine (2017 H7N9 IIV) manufactured by Seqirus Inc (Seqirus) administered at different dosages (3.75 microgram mcg, 7.5 mcg and 15 mcg of hemagglutinin (HA) per dose) given with MF59(R) adjuvant manufactured by Seqirus Inc., or without adjuvant (15 mcg of HA per dose). Phosphate buffered saline (PBS) diluent manufactured by Patheon Manufacturing Services LLC will be used to achieve certain targeted doses. Approximately 371 subjects who are in good health and meet all eligibility criteria will be randomized into one of 4 study groups. The study will be conducted at up to 7 Vaccine and Treatment Unit (VTEU) sites and will last approximately 17 months, with subject participation duration of approximately 13 months. The Primary Objectives of the study are: 1) To assess the safety and reactogenicity following receipt of two doses of 2017 H7N9 IIV administered intramuscularly (IM) at different dosages approximately 21 days apart given with or without MF59(R) adjuvant; 2) To assess the serum hemagglutinin inhibition (HAI) and neutralizing (Neut) antibody responses approximately 21 days following receipt of two doses of 2017 H7N9 IIV administered IM at different dosages approximately 21 days apart with or without MF59(R) adjuvant.
This is a randomized, double-blinded, Phase II study in healthy males and non-pregnant females, 18-64 years of age. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of a pre-pandemic 2017 monovalent inactivated influenza A/H7N9 virus vaccine (2017 H7N9 IIV) manufactured by Seqirus Inc (Seqirus) administered at different dosages (3.75 mcg, 7.5 mcg and 15 mcg of hemagglutinin (HA) per dose) given with MF59(R) adjuvant manufactured by Seqirus Inc., or without adjuvant (15 mcg of HA per dose). Phosphate buffered saline (PBS) diluent manufactured by Patheon Manufacturing Services LLC will be used to achieve certain targeted doses. Approximately 371 subjects who are in good health and meet all eligibility criteria will be randomized into one of 4 study groups. The study will be conducted at up to 7 Vaccine and Treatment Unit (VTEU) sites and will last approximately 17 months, with subject participation duration of approximately 13 months. The Primary Objectives of the study are: 1) To assess the safety and reactogenicity following receipt of two doses of 2017 H7N9 IIV administered intramuscularly (IM) at different dosages approximately 21 days apart given with or without MF59(R) adjuvant; 2) To assess the serum hemagglutinin inhibition (HAI) and Neutralizing (Neut) antibody responses approximately 21 days following receipt of two doses of 2017 H7N9 IIV administered IM at different dosages approximately 21 days apart with or without MF59(R) adjuvant. The secondary Objectives are: 1) To assess all unsolicited non-serious Adverse Events (AEs) following receipt of two doses of a 2017 H7N9 IIV administered IM at different dosages approximately 21 days apart with or without MF59(R) adjuvant; 2) To assess medically-attended adverse events (MAAEs) including new-onset chronic medical conditions (NOCMCs), potentially immune-mediated medical conditions (PIMMCs), and all Serious Adverse Events (SAEs) following receipt of two doses of a 2017 H7N9 IIV administered IM at different dosages approximately 21 days apart with or without MF59(R) adjuvant; 3) To assess the serum HAI and Neut antibody responses approximately 7 and 21 days following receipt of a single dose, and approximately 7 days following receipt of two doses of 2017 H7N9 IIV administered IM at different dosages approximately 21 days apart with or without MF59(R) adjuvant. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01698060 -
Immunogenicity of ND1.1 by Delivery Directly to the Ileum
|
Phase 1 | |
Completed |
NCT02213354 -
H7N9 Mix and Match With MF59 in Healthy Elderly Persons
|
Phase 2 | |
Completed |
NCT02295813 -
Safety and Pharmacokinetics Study of FBF001
|
Phase 1 | |
Completed |
NCT00561184 -
Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine
|
Phase 2 | |
Completed |
NCT02921997 -
H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses
|
Phase 2 | |
Completed |
NCT00895544 -
Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in Adults
|
Phase 1/Phase 2 | |
Completed |
NCT02251288 -
A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine
|
Phase 1 | |
Completed |
NCT02612909 -
A Safety and Immunogenicity Study of IVACFLU-A/H5N1
|
Phase 2/Phase 3 | |
Completed |
NCT02229357 -
Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine
|
Phase 2 | |
Completed |
NCT01150552 -
Studies of Avian Influenza Transmission to Humans in Egypt
|
N/A | |
Completed |
NCT03472976 -
H5N1 With or Without Topical Aldara in Healthy Adults
|
Phase 1 | |
Completed |
NCT01897701 -
A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1
|
Phase 1 | |
Completed |
NCT01107262 -
Avian Influenza Studies In Lebanon
|
N/A | |
Completed |
NCT02839330 -
A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age
|
Phase 3 | |
Completed |
NCT03014310 -
H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology
|
Phase 1 | |
Completed |
NCT00298233 -
High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza
|
Phase 2 | |
Completed |
NCT03318315 -
Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4
|
Phase 2 | |
Completed |
NCT03312231 -
Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly
|
Phase 2 | |
Completed |
NCT03738241 -
2017 A/H7N9 IIV Revaccination
|
Phase 2 | |
Completed |
NCT03589807 -
2013/2017 H7N9 Prime-Boost Interval
|
Phase 2 |